Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Using Furosemide and Hydrochlorothiazide for Treating Patients with Acute Heart Failure

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on studying the treatment of Acute Heart Failure, a condition where the heart suddenly becomes unable to pump blood effectively. The study will use medications called Furosemide and Hydrochlorothiazide, which are diuretics. Diuretics help the body get rid of excess fluid by increasing urine production. Furosemide will be administered either as a solution for injection or in tablet form, while Hydrochlorothiazide will be given as a tablet.

The purpose of the study is to evaluate how well these treatments can resolve congestion, which is the buildup of fluid in the body, within the first 72 hours of treatment. Congestion is a common problem in patients with heart failure and can lead to symptoms like swelling and difficulty breathing. The study will compare the standard treatment approach with an intervention that uses measurements of intra-abdominal pressure and ultrasound to guide the treatment. Intra-abdominal pressure refers to the pressure within the abdomen, and ultrasound is a technique that uses sound waves to create images of the inside of the body.

Participants in the study will receive either the standard treatment or the intervention treatment. The study will monitor the effectiveness of the treatments in reducing congestion over a period of time. The goal is to determine which approach is more effective in helping patients with acute heart failure recover more quickly and comfortably. The study is expected to continue until 2026.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on criteria such as age, diagnosis of heart failure, and specific blood test results.

    Informed consent is required to participate in the study.

  2. Step 2

    Initial assessment

    An initial assessment is conducted, which includes measuring intra-abdominal pressure and performing a clinical ultrasound.

    These assessments help guide the diuretic treatment plan.

  3. Step 3

    Intravenous diuretic treatment

    The treatment begins with the administration of furosemide intravenously. This medication helps reduce fluid buildup in the body.

    The goal is to achieve complete resolution of congestion within the first 72 hours of treatment.

  4. Step 4

    Oral medication administration

    In addition to intravenous treatment, furosemide and hydrochlorothiazide are administered orally.

    These medications are taken to maintain the reduction of fluid buildup.

  5. Step 5

    Monitoring and evaluation

    Throughout the treatment, regular monitoring is conducted to evaluate the effectiveness of the diuretic therapy.

    The absence of congestion is assessed using the ADVOR scale after 72 hours.

  6. Step 6

    Completion of the trial

    The trial concludes with a final evaluation to determine the success of the treatment in resolving congestion.

    The study is estimated to end by September 30, 2026.

Who can join the trial?

6 criteria

  • Men or women over 18 years of age
  • Diagnosis of HF (Heart Failure) based on the latest guidelines published in 2022
  • NT-proBNP greater than 1000 pg/mL or BNP greater than 250 pg/mL. These are blood tests that help diagnose heart failure.
  • Bladder catheterization to measure intra-abdominal pressure. This involves placing a tube in the bladder to check pressure inside the abdomen.
  • Presence of congestion in the blood vessels or mixed areas, shown by signs like swelling (edema), fluid in the abdomen (ascites), or fluid around the lungs (pleural effusion)
  • Signature of the informed consent, which means agreeing to participate after understanding the study details

Who cannot join the trial?

4 criteria

  • Patients who do not have Acute Heart Failure cannot participate. Acute Heart Failure is a condition where the heart suddenly can't pump enough blood to meet the body's needs.
  • Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
  • Both male and female patients are eligible, so gender is not an exclusion criterion.
  • Patients who are considered part of a vulnerable population, such as those who might not be able to give informed consent, are not included in this study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Diuretics are medications used to help the body get rid of excess fluid by increasing urine production. In this trial, they are used to treat patients with acute heart failure by reducing fluid buildup in the body, which can help alleviate symptoms such as swelling and difficulty breathing. The trial aims to evaluate how effective diuretics are in resolving congestion within the first 72 hours of treatment.

What is already known about the treatment

Furosemide – Furosemide is typically administered intravenously or orally, depending on the patient's condition and the urgency of treatment. It is a well-established medication in medical literature, primarily used for its diuretic effects to treat conditions like acute heart failure. The main therapeutic indication for furosemide is to reduce fluid overload by promoting the excretion of excess water and salt through the kidneys. At the molecular level, it works by inhibiting the sodium-potassium-chloride cotransporter in the loop of Henle in the kidneys, leading to increased urine production. Furosemide is classified as a loop diuretic, which is a type of medication that helps remove excess fluid from the body.

Investigated diseases

Acute Heart Failure – This condition occurs when the heart suddenly becomes unable to pump blood effectively, leading to a rapid onset of symptoms. It often results in fluid buildup in the lungs and other parts of the body, causing shortness of breath, swelling, and fatigue. The heart's reduced ability to circulate blood can lead to congestion, which is a key feature of this disease. Acute heart failure can develop quickly, often within hours or days, and requires immediate medical attention. It may be triggered by factors such as heart attacks, high blood pressure, or other underlying heart conditions. The progression involves worsening symptoms if not managed promptly, emphasizing the need for timely intervention.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-512901-22-00Protocol codePI23/00797Estimated enrolment168 patientsSponsorFundacion Instituto De Investigacion Sanitaria Aragon

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.